Key Points: 

• Patients who used Ozempic or other GLP-1 drugs and were diagnosed with gastroparesis through a gastric emptying study may qualify to file a lawsuit. 
• Patients who used GLP-1 drugs and were diagnosed with NAION, an eye condition that can cause sudden and permanent vision loss, may also qualify. 
• Thousands of GLP-1 lawsuits are now pending in two separate federal multidistrict litigations in the Eastern District of Pennsylvania. 

Why It Matters 

Millions of Americans take Ozempic, Wegovy, Mounjaro, and other GLP-1 receptor agonist drugs to manage type 2 diabetes or to lose weight. While these medications work well for many patients, a growing body of research has linked them to two serious health conditions: gastroparesis, sometimes called stomach paralysis, and NAION, an eye condition that can cause permanent blindness. Patients who developed either of these conditions after taking a GLP-1 drug may be entitled to compensation, but the window to act is not unlimited. Understanding whether you qualify is the first step toward protecting your legal rights. 

Understanding the Ozempic and GLP-1 Lawsuits 

Lawsuits against the makers of Ozempic and other GLP-1 drugs allege that manufacturers Novo Nordisk and Eli Lilly failed to adequately warn patients and doctors about the risk of serious side effects.  

If you or a loved one used a GLP-1 medication and were later diagnosed with gastroparesis or NAION vision loss, you may qualify to file a lawsuit and recover compensation.  

Find out whether you have a case or start the process of filing your claim today by contacting the lawyers at Hissey Mulderig & Friend toll-free at 1-866-806-8117, or by filling the free claim submission form on the right side of this page. 

Who Qualifies to File a GLP-1 Lawsuit? 

Not everyone who experienced side effects from a GLP-1 drug will qualify to file a claim. Attorneys reviewing these cases are generally focused on two specific groups of patients: 

• People who used a GLP-1 drug and were diagnosed with gastroparesis that was confirmed through a gastric emptying study. 
• People who used a GLP-1 drug and were diagnosed with NAION, which stands for non-arteritic anterior ischemic optic neuropathy. 

Each of these injuries is explained in more detail below, along with the medical records that are typically needed to support a claim. 

Qualifying With a Gastroparesis Diagnosis 

Gastroparesis is a condition in which the stomach empties food into the small intestine too slowly, or stops emptying altogether, even though there is no physical blockage.  

Patients with gastroparesis often experience severe nausea, repeated vomiting, bloating, abdominal pain, early fullness after eating only a few bites, and unintended weight loss. In serious cases, the condition can lead to malnutrition, dehydration, and repeated hospitalizations. 

GLP-1 drugs work in part by slowing down digestion, which helps patients feel full longer. For some patients, however, this slowing effect appears to go too far. One study found that nearly 70 percent of emergency room visits involving GLP-1 side effects were caused by stomach problems, including gastroparesis. The prescribing label for Ozempic also states that the drug is not recommended for patients with severe gastroparesis. 

To qualify for a gastroparesis lawsuit, a patient generally must have a diagnosis that was confirmed through a gastric emptying study. A gastric emptying study, also known as gastric emptying scintigraphy, is a test in which a patient eats a small meal containing a tiny amount of radioactive material.  

A scanner then tracks how quickly the food leaves the stomach over the course of several hours. According to the National Institute of Diabetes and Digestive and Kidney Diseases, this test is the standard method doctors use to confirm delayed stomach emptying and diagnose gastroparesis. 

This diagnostic requirement matters because symptoms like nausea and vomiting can have many causes. A gastric emptying study provides objective medical evidence that the stomach itself has stopped working properly, which strengthens the connection between the patient’s injury and their use of a GLP-1 drug. 

Qualifying With a NAION Diagnosis 

The second group of patients who may qualify to file a GLP-1 lawsuit are those diagnosed with NAION after taking Ozempic or a similar drug.  

NAION, or non-arteritic anterior ischemic optic neuropathy, occurs when blood flow to the optic nerve is reduced or cut off, damaging the nerve and causing vision loss. The condition is sometimes described as an eye stroke. 

Vision loss from NAION is usually sudden and painless. Many patients notice the change when they wake up in the morning. The condition typically affects one eye at first, though roughly 15 percent of patients eventually lose vision in the other eye as well.  

There is currently no proven treatment that reverses vision loss caused by NAION, which means the damage is often permanent. 

The link between GLP-1 drugs and NAION first drew widespread attention in 2024, when researchers at Massachusetts Eye and Ear published a study in JAMA Ophthalmology finding that diabetes patients taking semaglutide, the active ingredient in Ozempic and Wegovy, were roughly four times more likely to be diagnosed with NAION than patients taking other diabetes medications.  

Among patients who were overweight or obese, the risk was even higher. More recently, a study in the British Journal of Ophthalmology found that Wegovy users may face nearly five times the risk of ischemic optic neuropathy compared to patients taking Ozempic. 

To qualify for a lawsuit, a patient generally must have a documented NAION diagnosis from an ophthalmologist or other eye care provider, along with records showing they used a GLP-1 drug before their vision loss began.  

Patients with questions about the condition and the litigation can find answers on our NAION frequently asked questions page. 

Which Drugs Are Included in the Litigation? 

The GLP-1 lawsuits involve several widely prescribed medications, including: 

• Ozempic (semaglutide) 
• Wegovy (semaglutide) 
• Rybelsus (semaglutide) 
• Mounjaro (tirzepatide) 
• Trulicity (dulaglutide) 
• Saxenda (liraglutide) 

Patients who used any of these drugs and were later diagnosed with gastroparesis or NAION may qualify to file a claim, whether the medication was prescribed for diabetes or for weight loss. 

Where the Litigation Stands Today 

GLP-1 lawsuits are currently consolidated in two separate federal multidistrict litigations, or MDLs, both overseen by Judge Karen Marston in the Eastern District of Pennsylvania. An MDL is a legal process that groups similar lawsuits together before one judge to handle pretrial matters more efficiently, while each plaintiff keeps their own individual case. 

Gastrointestinal injury claims, including gastroparesis cases, are consolidated in MDL 3094, which now includes more than 3,800 pending lawsuits.  

Vision loss claims were placed in a separate NAION MDL, MDL 3163, which was created in December 2025 and has grown past 100 cases, with additional NAION lawsuits proceeding in New Jersey state court.  

Both litigations are still in their early stages, and no trials or settlements have taken place yet. Legal experts expect the number of filed cases to keep climbing as more patients learn about the risks associated with these drugs. 

Find Out if You Qualify to File a GLP-1 Lawsuit 

If you or a loved one used Ozempic, Wegovy, Mounjaro, or another GLP-1 medication and were diagnosed with gastroparesis through a gastric emptying study, or diagnosed with NAION, you may qualify to file a lawsuit and receive compensation.  

Our law firm, Hissey Mulderig & Friend, is currently investigating claims of gastroparesis or NAION linked to the use of GLP-1 medications like Ozempic. 

There is no cost to receive a consultation from an attorney, and there are no legal fees unless we recover compensation in your case. 

Schedule a free case review to find out if you qualify by calling our office toll-free at 1-866-806-8117, or you can contact us online today by filling out the form at the top of this page.